Abstracts tagged "Cohort Study"

Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Jessica Boivin¹, Karim Sacre², Sasha Bernatsky³, Ann E. Clarke⁴, Megan Barber⁴, Paul Fortin⁵, John Hanly⁶, Alexandra Legge⁷, Sang-Cheol Bae⁸ and Evelyne Vinet⁹, ¹McGill University, Montreal, QC, Canada, ²Université de Paris, Paris, France, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…
Abstract Number: 0749 • ACR Convergence 2024
Age at Disease Onset Influences the Clinical Phenotype and Outcome of Patients with Takayasu Arteritis: Results from a Monocentric Cohort of 167 Patients
Alessandro Tomelleri¹, Corrado Campochiaro², Elena Baldissera³, Nicola Farina⁴, Marco Matucci-Cerinic⁵ and Lorenzo Dagna⁶, ¹Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³IRCCS San Raffaele Hospital, Milan, Italy, ⁴Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milan, Italy, ⁵University San Raffaele Milano, Milano, Milan, Italy, ⁶Ospedale San Raffaele, Milano, Italy
Background/Purpose: Takayasu arteritis (TAK) typically affects people between the ages of 20 and 40. However, disease onset can span across different age periods. Aim of…
Abstract Number: 1151 • ACR Convergence 2024
Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy
Beibei Cui¹, Hongjiang Liu², Geng Yin³ and Qibing Xie⁴, ¹Rheumatology and Immunology, Chengdu, China (People's Republic), ²West China Hospital, Sichuan University, Chengdu, China (People's Republic), ³Department of Rheumatology and Immunology, chengdu, China (People's Republic), ⁴Department of Rheumatology and Immunology, Chengdu, Sichuan, China
Background/Purpose: The primary objective of this study was to comprehensively analyze the clinical characteristics of immune-mediated necrotizing myopathy (IMNM) and develop a reliable recurrence prediction…
Abstract Number: 1460 • ACR Convergence 2024
Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Lou Kawka¹, Jacques-Eric Gottenberg², Jérôme Avouac³, OLIVIER BROCQ⁴, GILLES HAYEM⁵, Xavier Mariette⁶, Alain Meyer⁷, BENOIT FLACHAIRE⁸, OLIVIER FOGEL⁹, ARTHUR GANDIOLLE¹⁰, MANON LESTURGIE¹¹, JEAN-FRANCOIS KLEINMANN¹², Samira Ahmed Yahia¹³ and Thao Pham¹⁴, ¹Hôpital Universitaire de Strasbourg, Strasbourg, Alsace, France, ²Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁵Groupe Hospitalier Paris Saint-Joseph, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁷UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁸Aix Marseille University, Marseille, France, ⁹AP-HP, Paris, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Cochin hospital, Paris, France, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Hôpital Universitaire de Strasbourg, Strasbourg, France, ¹⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: This study aimed to evaluate the clinical scenarios in which clinicians initiate cTT, as well as the safety and effectiveness of cTT in patients…
Abstract Number: 1725 • ACR Convergence 2024
Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering significant benefits in various malignancies. However, these therapies can induce immune-related adverse events (irAEs), including…
Abstract Number: 2233 • ACR Convergence 2024
Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Susan Manzi⁵, Michael Mahler⁶, Veena Joy⁷ and Tyler O'Malley⁸, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Werfen, San Diego, CA, ⁷ThermoFisher, Philadelphia, PA, ⁸Exagen, Vista, CA
Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…
Abstract Number: 2465 • ACR Convergence 2024
Subclinical Loss of Lung Volumes in Very Early SSc: Evidence from Two Independent Cohorts in EUSTAR
Vishal Kakkar¹, Stefano Di Donato², Silvia Bellando-Randone³, Riccardo Bixio⁴, Marco Matucci-Cerinic⁵, Yannick Allanore⁶ and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ³University of Florence, Florence, Florence, Italy, ⁴University of Verona, Verona, Verona, Italy, ⁵University San Raffaele Milano, Milano, Milan, Italy, ⁶Université Paris Cité, Paris, France
Background/Purpose: Interstitial lung disease (ILD) remains as the major driver of mortality in systemic sclerosis (SSc). The literature indicates that at the time of diagnosis…
Abstract Number: 0127 • ACR Convergence 2024
Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China
Chen Chen¹, Ao Zhang², Jianhui Cheng³, Zhongqiang Yao⁴, Juan Meng⁵, Yilu Qin⁶, Qingyi Lu¹, Yufei Li¹, Xiangjun Liu¹, Tianhao Li⁷, Chao Hou⁷, Yundi Tang¹, Hongjiang Liu⁸, Ning Xu¹, Sai Dong¹, Xinxin Li³, Fangmin Xu², Jianping Guo¹ and Chun Li¹, ¹Peking University People's Hospital, Beijing, China, ²Beijing University of Posts and Telecommunications, Beijing, China, ³State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China (People's Republic), ⁴Peking University Third Hospital, Beijing, China, ⁵Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China, ⁶Affiliated Xinxiang Central Hospital of Xinxiang Medical University, Xinxiang, China (People's Republic), ⁷Peking University Health Science Center, Beijing, China, ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a complex disease characterized by the presence of anti-phospholipid antibodies (aPLs). Its significant clinical heterogeneity brings clinical and therapeutical challenges.…
Abstract Number: 0464 • ACR Convergence 2024
Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
Amir Razmjou¹, Rong Guo², David Elashoff³, Kevin Deane⁴, Jill Norris⁵, Marie Feser⁶, Jennifer Wang¹, Ani Shahbazian² and christina Charles-Schoeman⁷, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Department of Medicine Statistics Core, Los Angeles, ⁴University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁵Colorado School of Public Health, Denver, CO, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷UCLA Medical Center, Santa Monica, CA
Background/Purpose: Rheumatoid arthritis (RA) has a well described pre-clinical state, with a continuum of genetic and environmental risk factors leading to the development of systemic…
Abstract Number: 0752 • ACR Convergence 2024
Non-classical Organ Involvement in Giant Cell Arteritis
Javier Narvaez-García¹, paola Vidal¹, Pol Maymó², Judith Palacios³, Martí Aguilar Coll¹, Monserrat Roig Kim¹, Laia De Daniel¹ and Joan Miquel Nolla¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge., Barcelona, Spain, ³Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain
Background/Purpose: The increasing use of imaging techniques, particularly 18F-FDG PET-CT, has significantly expanded our understanding of giant cell arteritis (GCA). Our aim was to examine…
Abstract Number: 1170 • ACR Convergence 2024
Computer Aided Lung Informatics, HRCT and PFT in Patients with Interstitial Lung Disease in Idiopathic Inflammatory Myopathies
Sonali Narain¹, Kourosh Shargani², Ivana Ilic³, Irvind Buttar⁴ and Galina Marder⁵, ¹Northwell Health, Great Neck, NY, ²Northwell, Manhasset, NY, ³Northwell, Brooklyn, NY, ⁴Northwell Health/ Lenox Hill Hospital, Dix Hills, NY, ⁵Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY
Background/Purpose: Evaluation of Interstitial Lung Disease (ILD) progression relies on high resolution computed tomography (HRCT) and pulmonary function test (PFT). As we previously reported in our Idiopathic…
Abstract Number: 1495 • ACR Convergence 2024
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Mawuena Binka¹, Rana Muhammad Qasim Khan², Joseph Tkacz³, Donna McMorrow³, Laurence Gozalo³ and Gail Kerr⁴, ¹BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, ³Inovalon, Bowie, MD, ⁴Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
Abstract Number: 1890 • ACR Convergence 2024
Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study
Dani Contreras¹, Zanir Bhanji¹, J. Antonio Avina-Zubieta², Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Ambulatory Care Sensitive Conditions (ACSCs) are conditions where appropriate access to ambulatory care could prevent or reduce complications, a more severe disease course, or…
Abstract Number: 2234 • ACR Convergence 2024
Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort
Sung Hae Chang¹, Yong-Beom Park², Gregory McDermott³, Misti Paudel⁴, Keigo Hayashi³, You-Jung Ha⁵, Jeong Seok Lee⁶, Min Uk Kim⁷, Chan Ho Park⁸, Sang Wan Chung⁹, Ji-Won Kim¹⁰, Jang Woo Ha¹¹, Sung Won Lee¹², Eun Ha Kang⁵, Yeon-Ah Lee¹³, Jung-Yoon Choe¹⁴, Eun Young Lee¹⁵ and Jeffrey Sparks¹⁶, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, ¹Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, ²Yonsei University College of Medicine, Seoul, Republic of Korea, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Seoul National University Bundang Hospital, Seongnam, South Korea, ⁶Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, ⁹Kyung Hee University Hospital, Seoul, Republic of Korea, ¹⁰Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, ¹¹Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, ¹²Soonchunhyang University Cheonan Hospital, Seoul, South Korea, ¹³Kyung Hee University Hospital, Seoul, South Korea, ¹⁴Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, ¹⁵3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ¹⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (ILD) is a heterogeneous disease with a chronic course and potential for flares. Serum biomarkers are needed to identify those…
Abstract Number: 2488 • ACR Convergence 2024
Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis
Sushmitha Inguva¹, Pallavi Rane¹, Darcy Trimpe¹, Sam Oh¹, Jasjit Multani², Hsiu-Ching Chang², Marie Yasuda², Chi-Chang Chen², Duvuru Geetha³, Peter Merkel⁴ and Zachary Wallace⁵, ¹Amgen Inc., Thousand Oaks, CA, ²IQVIA, Wayne, PA, ³Johns Hopkins University, Baltimore, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The United States (US) Food and Drug Administration approved avacopan to treat adults with severe active granulomatosis with polyangiitis or microscopic polyangiitis in October…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].